CMChristine N. Miller

Christine N. Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christine N. Miller has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Raj Chari

    Genome Modification Core, Laboratory Animal Sciences Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, USA

    2 shared publications
  • Acong Yang

    RNA Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA

    1 shared publication
  • Anatoly Kustanovich

    Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel

    1 shared publication
  • Beverly A. Mock

    National Institutes of Health

    1 shared publication
  • Bogdan Polevoda

    Department of Biochemistry and Biophysics, Center for RNA Biology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA

    1 shared publication
  • Brad St. Croix

    Tumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA

    1 shared publication

Latest Publications

  • Open Access

    Transfer RNA acetylation regulates in vivo mammalian stress signaling

    by Supuni Thalalla Gamage, Roxane Khoogar, Shereen Howpay Manage, Judey T. DaRos, McKenna C. Crawford, Joe Georgeson, Bogdan V. Polevoda, Chelsea Sanders, Kendall A. Lee, Kellie D. Nance, et al.

    Transfer RNA (tRNA) modifications are crucial for protein synthesis, but their position-specific physiological roles remain poorly understood. Here, we investigate the impact of N 4 -acetylcytidine (ac 4 C), a highly conserved tRNA modification catalyzed by the essential acetyltransferase Nat10. By targeting Thumpd1, a nonessential adapter protein required for Nat10-catalyzed tRNA acetylation, we determine that loss of tRNA acetylation leads to reduced levels of tRNA Leu , increased ribosome stalling, and activation of eIF2α phosphorylation. Thumpd1 knockout mice exhibit growth defects and sterility. Concurrent knockout of Thumpd1 and the stress-sensing kinase Gcn2 causes penetrant postnatal lethality in mice, indicating a critical genetic interaction. Our findings demonstrate that a modification restricted to a single position within type II cytosolic tRNAs can regulate ribosome-mediated stress signaling in mammalian organisms, with implications for our understanding of translational control and therapeutic interventions.


  • Open Access

    Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform

    by Liping Yang, Timothy P. Sheets, Yang Feng, Guojun Yu, Pradip Bajgain, Kuo-Sheng Hsu, Daeho So, Steven Seaman, Jaewon Lee, Ling Lin, et al.

    The majority of clinically approved drugs target proteins that are secreted or cell surface bound. However, further advances in this area have been hindered by the challenging nature of receptor deorphanization, as there are still many secreted and cell-bound proteins with unknown binding partners. Here, we developed an advanced screening platform that combines CRISPR-CAS9 guide–mediated gene activation (CRISPRa) and high-avidity bead-based selection. The CRISPRa platform incorporates serial enrichment and flow cytometry–based monitoring, resulting in substantially improved screening sensitivity for well-known yet weak interactions of the checkpoint inhibitor family. Our approach has successfully revealed that siglec-4 exerts regulatory control over T cell activation through a low affinity trans-interaction with the costimulatory receptor 4-1BB. Our highly efficient screening platform holds great promise for identifying extracellular interactions of uncharacterized receptor-ligand partners, which is essential to develop next-generation therapeutics, including additional immune checkpoint inhibitors.